The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Distribution of CB1 Cannabinoid Receptors in the Amygdala and their Role in the Control of GABAergic Transmission
Open accessAbstract
Cannabinoids are the most popular illicit drugs used for recreational purposes worldwide. However, the neurobiological substrate of their mood-altering capacity has not been elucidated so far. Here we report that CB1 cannabinoid receptors are expressed at high levels in certain amygdala nuclei, especially in the lateral and basal nuclei, but are absent in other nuclei (e.g., in the central nucleus and in the medial nucleus). Expression of the CB1 protein was restricted to a distinct subpopulation of GABAergic interneurons corresponding to large cholecystokinin-positive cells. Detailed electron microscopic investigation revealed that CB1 receptors are located presynaptically on cholecystokinin-positive axon terminals, which establish symmetrical GABAergic synapses with their postsynaptic targets. The physiological consequence of this particular anatomical localization was investigated by whole-cell patch-clamp recordings in principal cells of the lateral and basal nuclei. CB1 receptor agonists WIN 55,212-2 and CP 55,940 reduced the amplitude of GABA(A) receptor-mediated evoked and spontaneous IPSCs, whereas the action potential-independent miniature IPSCs were not significantly affected. In contrast, CB1 receptor agonists were ineffective in changing the amplitude of IPSCs in the rat central nucleus and in the basal nucleus of CB1 knock-out mice. These results suggest that cannabinoids target specific elements in neuronal networks of given amygdala nuclei, where they presynaptically modulate GABAergic synaptic transmission. We propose that these anatomical and physiological features, characteristic of CB1 receptors in several forebrain regions, represent the neuronal substrate for endocannabinoids involved in retrograde synaptic signaling and may explain some of the emotionally relevant behavioral effects of cannabinoid exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Following their synthesis, ECBs are retrogradely transported into the extracellular space to bind ECB receptors present on presynaptic terminals [19–21].”
From Amygdala FAAH and anandamide: mediating protection and recovery from stress (2013) · cites this paper as [19]
In the citing paper
“Within amygdala subnuclei, FAAH is highly expressed on pyramidal neurons in the BLA, and to a significantly lesser extent in the central nucleus (CeA) [19,20,46,47].”
From Amygdala FAAH and anandamide: mediating protection and recovery from stress (2013) · cites this paper as [19]
In the citing paper
“Yet, CB1 receptors are expressed at high levels in the BLA (Herkenham et al, 1990;Katona et al, 2001;Tsou et al, 1997)”
From Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress (2012) · cites this paper as Katona et al, 2001
In the citing paper
“but their expression in the central amygdala is less clear (Katona et al, 2001;Tsou et al, 1997;Cota et al, 2007; but see Kamprath et al, 2011).”
From Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress (2012) · cites this paper as Katona et al, 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218
Tanda, G., Pontieri, F. E., & Chiara, G. D. (1997) · Science · doi:10.1126/science.276.5321.2048 · Cited by 1,085
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M. A., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,078
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Kreitzer, A. C., & Regehr, W. G. (2001) · Neuron · doi:10.1016/s0896-6273(01)00246-x · Cited by 899
Ohno‐Shosaku, T., Maejima, T., & Kano, M. (2001) · Neuron · doi:10.1016/s0896-6273(01)00247-1 · Cited by 874
Mailleux, P., & Vanderhaeghen, J. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90409-u · Cited by 660
Cited by
Sorted by citations
Items 101–200 of 663
Gender effects on amygdala morphometry in adolescent marijuana users
McQueeny, T. M., Padula, C. B., Price, J. S., Lisdahl, K. M., Logan, P., & Tapert, S. F. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.031 · Cited by 145
“Specifically, animal research suggests that cannabinoid signaling alters amygdala functioning by facilitating long-term depression of GABAergic interneurons within the amygdala’s basolateral nucleus [13, 14].”
BackgroundMarco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 139
“Interestingly, these effects could be blocked by prior administration of AM630 (50 nM) supporting the involvement of CB2R in the effects of JWH133 on GABAergic signaling (Morgan et al., 2009).”
BackgroundInfluentialThe complications of promiscuity: endocannabinoid action and metabolism
Alexander, S. P. H., & Kendall, D. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707456 · Cited by 136
“Using antibodies that preferentially recognize the dimerized form of the CB1 receptor, it has been shown that this is apparently the preferred configuration of the receptors expressed in the brain (Hajos et al., 2000; Katona et al., 2001).”
BackgroundCampolongo, P., Trezza, V., Ratano, P., Palmery, M., & Cuomo, V. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1892-x · Cited by 133
“…modulate the release of several neurotransmitters implicated in the control of emotionality, such as serotonin, dopamine (Hermann et al. 2002; Katona et al. 2001; Schlicker and Kathmann 2001; Tsou et al. 1998) and the anxiogenic neuropeptides, CCK and CRF (Ameri 1999; Rodriguez de Fonseca et…”
BackgroundInfluentialLópez‐Moreno, J. A., González‐Cuevas, G., Moreno, G., & Navarro, M. A. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00105.x · Cited by 132
“…demonstrated that treatment of rats with WIN 55,212-2 and CP 55,940 suppresses the amplitude of GABAA receptormediated evoked and spontaneous inhibitory postsynaptic currents from spiny principal cells, neurons that connect fundamentally to each other with GABAergic synapses (Katona et al. 2001).”
BackgroundTargeting dopamine D2 and cannabinoid‐1 (CB1) receptors in rat nucleus accumbens
Pickel, V. M., Chan, J., Kearn, C. S., & Mackie, K. (2006) · The Journal of Comparative Neurology · doi:10.1002/cne.20881 · Cited by 128
Sumislawski, J. J., Ramikie, T. S., & Patel, S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.166 · Cited by 124
“CB1 receptors are highly expressed on axon terminals of GABAergic interneurons in the BLA and modulate GABA release via a presynaptic mechanism (Katona et al, 2001).”
BackgroundSpecific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal!
Grimsey, N. L., Goodfellow, C. E., Scotter, E. L., Dowie, M. J., Glass, M., & Graham, E. S. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.02.014 · Cited by 123
“Antibodies raised to the carboxy-terminus of CB1 have also been used to successfully detect receptors in rodent brain tissue, encompassing the entire carboxy-terminal region (Hajos et al., 2000; Katona et al., 2001; Bodor et al., 2005; Matyas et al., 2006) and also the last 13–15 amino acids (Egertova and Elphick, 200…”
MethodZhu, P., & Lovinger, D. M. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1148-05.2005 · Cited by 131
“These findings extend our knowledge of endocannabinoid signaling in the BLA, a brain region rich in endocannabinoids and CB 1 receptors (Katona et al., 2001; Marsicano et al., 2002).”
InfluentialVariations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces
Chakrabarti, B., Kent, L., Suckling, J., Bullmore, E. T., & Baron‐Cohen, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04697.x · Cited by 123
“This has implications for medical conditions involving hypo-responsivity to emotional and social stimuli, such as autism.”
BackgroundDistinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition
Hájos, N., & Freund, T. F. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00149-4 · Cited by 122
The Pharmacological Basis of Cannabis Therapy for Epilepsy
Reddy, D. S., & Golub, V. M. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.230151 · Cited by 128
“basolateral complex of the amygdala (Katona et al., 2001).”
BackgroundInfluentialGanon-Elazar, E., & Akirav, I. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.204 · Cited by 120
Di, S., Itoga, C. A., Fisher, M. O., Solomonow, J., Roltsch, E. A., Gilpin, N. W., & Tasker, J. G. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2279-15.2016 · Cited by 127
“CB1 receptors are highly expressed in the BLA, and are concentrated at presynaptic GABAergic terminals that synapse onto BLA principal neurons (Katona et al., 2001).”
BackgroundCannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve
Derbenev, A. V., Stuart, T. C., & Smith, B. N. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.067470 · Cited by 120
“…CB1R in DMV and NTS neurones in this and other studies (Van Sickle et al. 2003) may be partly due to immunolabelling of receptors that are manufactured or metabolized in DMV neurones, analogous to labelling patterns for interneurones of the hippocampus and amygdala (Katona et al. 1999, 2001).”
BackgroundResultInfluentialNeuron‐type specific cannabinoid‐mediated G protein signalling in mouse hippocampus
Steindel, F., Lerner, R., Häring, M., Ruehle, S., Marsicano, G., Lutz, B., & Monory, K. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12137 · Cited by 119
“…is visible in the strata molecularis > radiatum and > oriens, where the CB1 signal is predominantly originating from the interconnecting network of inhibitory interneurons innervating the dendritic arbour of pyramidal or granular cell bodies (Katona et al. 1999, 2001; Egertov a and Elphick 2000).”
BackgroundCannabinoid receptor homo- and heterodimerization
Mackie, K. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.011 · Cited by 119
Passie, T., Emrich, H. M., Karst, M., Brandt, S. D., & Halpern, J. H. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1377 · Cited by 117
“The hippocampal formation has an unusually high density of CB1 receptors [80] and these are involved in both glutamatergic and GABAergic presynaptic processes.([81]) CB1 receptors are present on certain peri-terminal axons at astonishingly high densities,([82]) enabling endogenous and exogenous cannabinoids to potentl…”
BackgroundYoshida, T., Uchigashima, M., Yamasaki, M., Katona, I., Yamazaki, M., Sakimura, K., Kano, M., Yoshioka, M., & Watanabe, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012875108 · Cited by 117
“Consistent with previous reports (12, 13, 15, 16), CB1 mRNA was expressed in various amygdala nuclei with the highest level in the BA (Fig.”
ResultRole of the endocannabinoid system in drug addiction
Manzanares, J., Cabañero, D., Puente, N., García‐Gutiérrez, M. S., Grandes, P., & Maldonado, R. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.013 · Cited by 118
Pistis, M., Perra, S., Pillolla, G., Melis, M., Gessa, G., & Muntoni, A. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.08.003 · Cited by 124
Contextual Inhibitory Gating of Impulse Traffic in the Intra‐amygdaloid Network
Paré, D., Royer, S., Smith, Y., & Lang, E. J. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07073.x · Cited by 114
Basavarajappa, B. S. (2007) · Current Neuropharmacology · doi:10.2174/157015907780866910 · Cited by 115
“cally on GABAergic interneurons and glutamatergic neurons [131, 132, 162, 163].”
BackgroundNeuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
Nathan, P. J., O’Neill, B. V., Napolitano, A., & Bullmore, E. T. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00172.x · Cited by 115
“The cannabinoid type 1 (CB1) receptors are widely distributed in the central nervous system, located mainly in presynaptic terminals of neurons [100] and in particular, on GABAergic interneurons expressing the α2 subunit enriched GABAA receptors [101,102].”
BackgroundHuang, H., Acuna, C., Li, Y., Cheng, H. M., Obrietan, K. H., & van den Pol, A. N. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0732-07.2007 · Cited by 115
“CB1Rs have been shown to be coupled to G-protein (usually the Gi subtype) and are often located on the presynaptic membrane of inhibitory axons (Tsou et al., 1998; Katona et al., 1999, 2001).”
Endocannabinoids and Traumatic Brain Injury
Mechoulam, R., & Shohami, E. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-8008-6 · Cited by 111
“These receptors have been shown to be localized presynaptically on GABAergic interneurons and glutamatergic neurons (Hajos et al., 2000; Hajos et al., 2001; Katona et al., 2001).”
BackgroundOsei‐Hyiaman, D., DePetrillo, M. A., Harvey-White, J. D., Bannon, A. W., Cravatt, B. F., Kuhar, M. J., Mackie, K., Palkovits, M., & Kunos, G. (2005) · Neuroendocrinology · doi:10.1159/000087925 · Cited by 110
“and here we documented co-localization of CART-immunoreactive fibers and CB1 receptors in the amygdala. Bidirectional connections between the two systems can be demonstrated immunohistochemically, although the highest levels of CART and CB1 immunoreactivity are in different amygdaloid nuclei (fig. 8 ). CB1 receptor-im…”
BackgroundPorter, B. A., & Mueller, T. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00608 · Cited by 104
“The zebrafish amygdala consists of three functional networks similar to the situation described for mammals: (1) the main olfactory system, (2) the accessory olfactory-like or reproductive amygdala, and (3) the central and pallial amygdala (CeA-pAmy) network (mammalian BLA) regulating autonomic functions and mediating…”
BackgroundInfluentialLever, I. J., & Rice, A. S. C. (2007) · Springer eBooks · doi:10.1007/978-3-540-33823-9_10 · Cited by 108
Gadd, C. A., Murtra, P., Felipe, C. D., & Hunt, S. P. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-23-08271.2003 · Cited by 107
Functional mapping of GABAA receptor subtypes in the amygdala
Marowsky, A., Fritschy, J., & Vogt, K. E. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03574.x · Cited by 107
“We focused on the type 1 cannabinoid receptor (CB1) as it is clearly expressed only on a subset of interneurons in the lateral ⁄ basolateral amygdala (Marsicano & Lutz, 1999; Katona et al., 2001).”
BackgroundBimodal Control of Fear-Coping Strategies by CB 1 Cannabinoid Receptors
Metna‐Laurent, M., Gómez, E. S., Verrier, D., Conforzi, M., Jégo, P., Lafenêtre, P., & Marsicano, G. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1054-12.2012 · Cited by 111
“BLA neurons contain CB1 receptors both at glutamatergic neurons and GABAergic interneurons (Marsicano and Lutz, 1999; Katona et al., 2001, 2006; Bellocchio et al., 2010).”
BackgroundSpagnolo, P. A., Ramchandani, V. A., Schwandt, M. L., Kwako, L. E., George, D. T., Mayo, L. M., Hillard, C. J., & Heilig, M. A. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13210 · Cited by 112
“Unlike most neurotransmitters, AEA and 2-AG are not stored in releasable pools; instead, they are rapidly synthesized “on-demand” and subserve retrograde regulation of synaptic activity through engaging presynaptic CB1R (Katona et al., 2001, Gulyas et al., 2004), and inhibiting neurotransmitter release (Bisogno et al.…”
BackgroundInfluentialHaller, J., Mátyás, F., Soproni, K., Varga, B., Barsy, B., Németh, B., Mikics, É., Freund, T. F., & Hájos, N. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05476.x · Cited by 103
“Experiments were carried out in accordance with the European Communities Council Directive of 24 November 1986 (86 ⁄ 609 ⁄ EEC) and were reviewed and approved by the Animal Welfare Committee of the Institute of Experimental Medicine.”
BackgroundMethodEggan, S. M., Stoyak, S. R., Verrico, C. D., & Lewis, D. A. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.75 · Cited by 106
“…and undergo nearly identical changes in laminar distribution during postnatal development (Oeth and Lewis, 1993; Eggan et al , 2010); and 3) the antibody utilized in this study exclusively labels symmetric, inhibitory synapses (Katona et al , 1999; Katona et al , 2001; Eggan and Lewis, 2007).”
Akirav, I. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00034 · Cited by 102
“CB 1 receptors are expressed in multiple brain areas, including the olfactory bulb, neocortex, pyriform cortex, hippocampus, amygdala, basal ganglia, thalamic and hypothalamic nuclei, cerebellar cortex, and brainstem nuclei (Herkenham et al., 1990, 1991; Katona et al., 2001).”
BackgroundType-1 Cannabinoid Receptor Signaling in Neuronal Development
Gaffuri, A.-L., Ladarré, D., & Lenkei, Z. (2012) · Pharmacology · doi:10.1159/000339075 · Cited by 107
Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System
Augustin, S. M., & Lovinger, D. M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00508 · Cited by 100
Atsak, P., Roozendaal, B., & Campolongo, P. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.047 · Cited by 98
Ganon-Elazar, E., & Akirav, I. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.01.014 · Cited by 98
“, amygdala, hippocampus and cerebral cortex) (Fuxe and Agnati, 1985; van Eekelen et al., 1987; Ahima and Harlan, 1990; Herkenham et al., 1990; Katona et al., 2001; Korte, 2001; Bentz et al., 2010).”
BackgroundRodgers, R. J., Evans, P., & Murphy, A. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00013 · Cited by 101
“areas long associated with the regulation of emotional behaviour, including the hippocampus and amygdala (Herkenham et al., 1991; Matsuda et al., 1993; Tsou et al., 1999; Katona et al., 2001), where their activation is typically associated with presynaptically mediated inhibition of transmitter release (Schlicker and…”
BackgroundBucherelli, C., Baldi, E., Mariottini, C., Passani, M. B., & Blandina, P. (2006) · Learning & Memory · doi:10.1101/lm.326906 · Cited by 105
“Noteworthy, CB1-r are present in the amygdala (Katona et al. 2001), where they are involved in long-term depression of”
BackgroundGamma oscillation deficits and the onset and early progression of schizophrenia
Woo, T.-U. W., Spencer, K., & McCarley, R. W. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003747609 · Cited by 96
Lorenzetti, V., Solowij, N., Fornito, A., Lubman, D. I., & Yücel, M. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990435 · Cited by 99
“, including the hippocampus, amygdala, PFC and cerebellum) high in CB1 receptors [47-56] and mediating emotional [57-65] and neurocognitive processes that are altered with regular cannabinoid exposure [6, 66-77].”
BackgroundWolf, O. T., Atsak, P., de Quervain, D. J. ‐., Roozendaal, B., & Wingenfeld, K. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12353 · Cited by 101
Harkany, T., Holmgren, C. D., Härtig, W., Qureshi, T., Chaudhry, F. A., Storm‐Mathisen, J., Dobszay, M. B., Berghuis, P., Schulte, G., Sousa, K. M., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4884-03.2004 · Cited by 97
“5% Triton X-100 in PB for 1 hr, which was followed by exposure to the primary antibody (Ab) rabbit anti-CB1 receptor [1:400; directed against a C-terminal sequence (Katona et al., 2001)] that was diluted in a mixture of 5% dimethylsulfoxide, 0.”
InfluentialEndocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration
Basavarajappa, B. S., Nixon, R. A., & Arancio, O. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787847921 · Cited by 98
“CB1 receptors have been shown to localize presynaptically on GABAergic interneurons and glutamatergic neurons [134-136].”
BackgroundMorozov, Y. M., Torii, M., & Rakic, P. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhp028 · Cited by 94
Marsicano, G., & Kuner, R. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3_10 · Cited by 103
Endocannabinoid signaling and the hypothalamic-Pituitary-Adrenal axis
Hillard, C. J., Beatka, M., & Sarvaideo, J. (2016) · Comprehensive physiology · doi:10.1002/cphy.c160005 · Cited by 93
“Early autoradiographic studies of the distribution of CB1R revealed the predominant expression of the receptor on axon terminals in the cerebellum (45) and this distribution pattern has been confirmed throughout the brain (79,80,119).”
CB1 receptor signaling regulates social anxiety and memory
Litvin, Y., Phan, A., Hill, M. N., Pfaff, D. W., & McEwen, B. S. (2013) · Genes Brain & Behavior · doi:10.1111/gbb.12045 · Cited by 99
“…to act as retrograde messengers at presynaptic CB1 receptors located on glutamatergic and gamma-aminobutyric acid (GABA)ergic axon terminals (Katona et al. 2001, 2006) to suppress neurotransmitter release (Wilson & Nicoll 2001), which in turn control synaptic plasticity (Katona & Freund…”
BackgroundTan, H., Lauzon, N. M., Bishop, S. F., Chi, N., Bechard, M., & Laviolette, S. R. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4718-10.2011 · Cited by 92
“Within the BLA, CB1 receptors are found on inhibitory local GABAergic interneurons, but are absent in the adjacent central nucleus (Herkenham et al., 1990; Tsou et al., 1998; Katona et al., 2001).”
BackgroundThe endocannabinoid system as a target for the treatment of cannabis dependence
Clapper, J. R., Mangieri, R. A., & Piomelli, D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.018 · Cited by 94
“Moderate receptor levels are also present in the basolateral amygdala, hypothalamus, and the periaqueductal gray matter of the midbrain (Glass et al., 1997; Herkenham et al., 1991; Katona et al., 2001; Matsuda et al., 1993).”
BackgroundModulatory effects of cannabinoids on brain neurotransmission
Cohen, K., Weizman, A., & Weinstein, A. M. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14407 · Cited by 98
Tambaro, S., & Bortolato, M. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842269 · Cited by 93
“The bidirectional action of CB1 receptors on anxiety responses may be related to the modulatory role of these targets on GABA and glutamate release across amygdala and other forebrain areas [41,165,166].”
BackgroundRodgers, R. J., Haller, J., Halász, J., & Mikics, É. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02548.x · Cited by 88
Pistis, M., Muntoni, A. L., Pillolla, G., & Gessa, G. L. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02019.x · Cited by 88
“amygdala (Katona et al., 2001), the hippocampus, the PFC (Mailleux”
BackgroundSegev, A., Rubin, A. S., Abush, H., Richter‐Levin, G., & Akirav, I. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.292 · Cited by 90
Bossong, M. G., van Hell, H. H., Jager, G., Kahn, R. S., Ramsey, N. F., & Jansma, J. M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.06.009 · Cited by 99
“Cannabinoid receptors are highly expressed in many of the key regions for emotional processing (Herkenham et al., 1991; Katona et al., 2001), such as the occipital and temporal lobes, which are involved in perceptual emotional processing, the amygdala and orbital frontal cortex, which are involved…”
BackgroundThe Role of the Brain's Endocannabinoid System in Pain and Its Modulation by Stress
Corcoran, L., Roche, M., & Finn, D. P. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.10.003 · Cited by 90
Cannabis: A Treasure Trove or Pandora's Box?
Solymosi, K., & Köfalvi, A. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557516666161004162133 · Cited by 93
Kamprath, K., Romo-Parra, H., Häring, M., Gaburro, S., Doengi, M., Lutz, B., & Pape, H.-C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.196 · Cited by 86
“In the same study, the authors failed to detect cannabinoid effects in the CeA by electrophysiological means (Katona et al, 2001), whereas another recent electrophysiological study reported that endocannabinoids regulate inhibitory transmission in the CeA (Roberto et al, 2010).”
BackgroundThe endocannabinoid system and nondrug rewarding behaviours
Fattore, L., Melis, M., Fadda, P., Pistis, M., & Fratta, W. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.020 · Cited by 96
“The BLA expresses high levels of CB1 receptors (Herkenham et al., 1991; Katona et al., 2001; McDonald and Mascagni, 2001) and CB1 mRNA (Marsicano and Lutz, 1999).”
BackgroundImmunolocalization of CB 1 receptor in rat striatal neurons: A confocal microscopy study
Fusco, F. R., Martorana, A., Giampà, C., March, Z. D., Farini, D., D’Angelo, V., Sancesario, G., & Bernardi, G. (2004) · Synapse · doi:10.1002/syn.20047 · Cited by 83
Atsak, P., Hauer, D., Campolongo, P., Schelling, G., Fornari, R. V., & Roozendaal, B. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.334 · Cited by 85
“CCK interneurons are proposed to function as fine-tuning devices for the cooperation of pyramidal neurons, and are sensitive to the emotional and motivational state of the animal (Katona et al, 2001; Yoshida et al, 2011).”
BackgroundEndocannabinoids, cannabinoids and the regulation of anxiety
Petrie, G. N., Nastase, A. S., Aukema, R. J., & Hill, M. N. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108626 · Cited by 91
Roche, M., O'Connor, E., Diskin, C., & Finn, D. P. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05861.x · Cited by 83
“interneurons in the BLA but absent from the central amygdaloid nucleus (Herkenham et al., 1990; Tsou et al., 1998; Katona et al., 2001).”
BackgroundRoberto, M., Cruz, M. T., Bajo, M., Siggins, G. R., Parsons, L. H., & Schweitzer, P. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.70 · Cited by 85
“CB1 ligands have been shown to diminish inhibitory transmission in the basal and lateral nuclei of the amygdala (Marsicano et al., 2002; Azad et al., 2003) but reportedly had no effect in CeA (Katona et al., 2001), in contrast with our results.”
Serrano, A., Rivera, P., Pavón, F. J., Decara, J. M., Suárez, J., de Fonseca, F. R., & Parsons, L. H. (2011) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01686.x · Cited by 86
“In other words, even relatively large EtOH-induced changes in the expression of endocannabinoid-related genes in the CeA may be masked by the much greater presence of ECS genes in the BLA.”
BackgroundInfluentialGABAergic cell type diversity in the basolateral amygdala
Capogna, M. (2014) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.01.006 · Cited by 91
“Another cell population that expresses cholecystokinin (CCK), often together with CB and type 1 cannabinoid (CB1) receptors [27] makes synapses with somata [28], suggesting analogy with cortical CCK-expressing basket cells [29].”
Freundt-Revilla, J., Kegler, K., Baumgärtner, W., & Tipold, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181064 · Cited by 88
Oudin, M. J., Hobbs, C., & Doherty, P. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07831.x · Cited by 81
“Indeed, CB1 was found on GABAergic interneurons, located presynaptically on cholecystokinin (CCK)-immunoreactive basket cells (Katona et al., 1999, 2001; Tsou et al., 1999; Hájos et al., 2000).”
BackgroundBhaskaran, M. D., & Smith, B. N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010683 · Cited by 82
“The usual cellular location for the CB1R in the hippocampus and other brain regions is synaptic terminals of GABAergic interneurons and select glutamatergic principal cells [24,25,26,27,28].”
Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain
Davis, M. P. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.1.85 · Cited by 82
“CB1 receptors can be found on presynaptic neuron membranes of GABAergic interneurons [10,21,22] .”
BackgroundWilkerson, J. L., Ghosh, S., Mustafa, M., Abdullah, R. A., Niphakis, M. J., Cabrera, R., Maldonado, R. L., Cravatt, B. F., & Lichtman, A. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.015 · Cited by 78
“…is predominately expressed on presynaptic neurons in the brain (Huang et al., 2001; Szabo and Schlicker, 2005), particularly GABAergic interneurons (Katona et al., 2001), and the CB2 receptor is highly expressed on immune cells (Carayon et al., 1998; Galiegue et al., 1995; Schatz et al., 1997).”
Tan, H., Lauzon, N. M., Bishop, S. F., Bechard, M. A., & Laviolette, S. R. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp210 · Cited by 81
“Within the BLA, CB1 receptors are highly expressed on inhibitory local c-aminobutyric acidergic (GABAergic) interneurons but are absent in the adjacent central nucleus (Herkenham et al. 1990; Tsou et al. 1998; Katona et al. 2001).”
BackgroundThe role of endocannabinoid transmission in cocaine addiction
Arnold, J. C. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.02.015 · Cited by 81
Vereczki, V., Veres, J. M., Müller, K., Nagy, G. A., Rácz, B., Barsy, B., & Hájos, N. (2016) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2016.00020 · Cited by 79
“…of PCs in the BLA is exclusively innervated by GABAergic boutons, which were immunoreactive for type 1 cannabinoid receptors (CB1), or the Ca2+ binding proteins parvalbumin (PV), and/or calbindin (Calb) (Katona et al., 2001; McDonald and Betette, 2001; McDonald et al., 2002; Muller et al., 2006).”
BackgroundRamikie, T. S., Nyilas, R., Bluett, R. J., Gamble‐George, J., Hartley, N. D., Mackie, K., Watanabe, M., Katona, I., & Patel, S. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.012 · Cited by 81
“Consistent with our anatomical data, we found that activation of CB1 receptors reliably reduced eEPSC amplitude, while effects on GABAergic transmission were more variable (Katona et al., 2001).”
InfluentialSchafer, S. M., Geuter, S., & Wager, T. D. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.008 · Cited by 79
“Specifically, FCA is mediated by increased cannabinoid activity (Rea et al., 2013) and decreased concentration of GABA (Rea et al., 2009) within BLA, consistent with both the high concentration of CB-1 receptors (Katona et al., 2001) and the inhibition of GABAergic neurons by cannabinoids.”
Cannabinoid modulation of the dopaminergic circuitry: Implications for limbic and striatal output
Fitzgerald, M. L., Shobin, E., & Pickel, V. M. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.004 · Cited by 80
Grey Matter Changes Associated with Heavy Cannabis Use: A Longitudinal sMRI Study
Koenders, L., Cousijn, J., Vingerhoets, W. A. M., van den Brink, W., Wiers, R. W. H. J., Meijer, C. J., Machielsen, M. W. J., Veltman, D. J., Goudriaan, A. E., & de Haan, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152482 · Cited by 83
“Both the amygdala [41, 42] and the hippocampal region [43] contain high levels of cannabinoid receptors making these regions likely to be affected by heavy as opposed to incidental cannabis use.”
Knerlich‐Lukoschus, F., Noack, M., von der Ropp‐Brenner, B., Lucius, R., Mehdorn, H. M., & Held‐Feindt, J. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2010.1652 · Cited by 79
“The findings of Katona and colleagues substantiated an important role of CB 1 activity in basolateral amygdala complex (BLA) projections that are involved in circuits regulating rewarding effects and reduction of anxiety responses (Katona et al., 2001).”
Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate
Rea, K., Roche, M., & Finn, D. P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707440 · Cited by 81
Yamasaki, M., Hashimoto, K., & Kano, M. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.2258-05.2006 · Cited by 78
Abush, H., & Akirav, I. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.51 · Cited by 77
“Both GR and CB1 receptors are located within the stress circuitry in the brain (ie, amygdala, hippocampus, and PFC) (Ahima and Harlan, 1990; Herkenham et al, 1990; Katona et al, 2001; van Eekelen et al, 1987).”
BackgroundEndocannabinoids: Effectors of glucocorticoid signaling
Balsevich, G., Petrie, G. N., & Hill, M. N. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.07.005 · Cited by 82
“Within the amygdala, CB1 receptors are located on both glutamatergic and GABAergic terminals (Katona et al., 2001; Marsicano and Lutz, 1999; McDonald and Mascagni, 2001), yet CB1-mediated suppression of glutamate transmission dominates, resulting in an overall reduction in the firing activity of basolateral amygdala (…”
BackgroundRole of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia
Connell, K., Bolton, N., Olsen, D., Piomelli, D., & Hohmann, A. G. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.12.008 · Cited by 76
Functional neuroanatomy of the basolateral amygdala: Neurons, neurotransmitters, and circuits
McDonald, A. J. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-815134-1.00001-5 · Cited by 84
“Furthermore, there was no change in the number of CCK+ perisomatic terminals contacting fear neurons, but an upregulation of CB1Rs in CCK+ terminals contacting fear neurons that were still active after extinction.”
BackgroundResultInfluentialWithdrawal from THC during adolescence: Sex differences in locomotor activity and anxiety
Harte‐Hargrove, L. C., & Dow-Edwards, D. L. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.02.048 · Cited by 73
Bhattacharyya, S., Egerton, A., Kim, E., Rosso, L., Barros, D. A. R., Hammers, A., Brammer, M. J., Turkheimer, F., Howes, O. D., & McGuire, P. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-14203-4 · Cited by 73
Tan, H., Ahmad, T., Loureiro, M., Zunder, J. S., & Laviolette, S. R. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00073 · Cited by 72
Harkany, T., Härtig, W., Berghuis, P., Dobszay, M. B., Zilberter, Y., Edwards, R. H., Mackie, K., & Ernfors, P. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02898.x · Cited by 72
Enhancement of endocannabinoid signaling and the pharmacotherapy of depression
Mangieri, R. A., & Piomelli, D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.003 · Cited by 73
Schmid, H. H. O., Schmid, P. C., & Berdyshev, E. V. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00157-3 · Cited by 71
Silva-Cardoso, G. K., Lazarini-Lopes, W., Hallak, J. E. C., Crippa, J. A. S., Zuardi, A. W., Garcia‐Cairasco, N., & Leite‐Panissi, C. R. A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108712 · Cited by 81
The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia
Volk, D. W., & Lewis, D. A. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.015 · Cited by 73
CB1 cannabinoid receptor-mediated aggressive behavior
Rodríguez‐Arias, M., Navarrete, F., Daza‐Losada, M., Navarro, D., Aguilar, M. A., Berbel, P. J., Miñarro, J., & Manzanares, J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.013 · Cited by 72
“areas, including the limbic system (hypothalamus, amygdala, habenula and cerebral cortex) regulating emotional and stressrelated behavior (Herkenham et al., 1990; Katona et al., 2001; Marsicano et al., 2002; Mackie, 2005).”
Cannabinoid Receptors: A brief history and "what's hot".
Graham, E. S. (2009) · Frontiers in bioscience · doi:10.2741/3288 · Cited by 71
Neuronal diversity of the amygdala and the bed nucleus of the stria terminalis
Beyeler, A., & Dabrowska, J. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-815134-1.00003-9 · Cited by 74
“Part of CR interneurons express VIP and/or CCK (Spampanato et al., 2011).”
BackgroundInfluential
Metadata
- Authors
- Katona, I., Rancz, E. A., Acsády, L., Ledent, C., Mackie, K., Hájos, N., & Freund, T. F.
- Affiliations
- HUN-REN Institute of Experimental Medicine (HU)
- Université Libre de Bruxelles (BE)
- University of Washington (US)
- ORCID
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2001-12-01
- Volume
- 21
- Issue
- 23
- Pages
- 9506-9518
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6763903
- OpenAlex
- W2153392906
- Cited by
- 668
- References
- 59
- Citations by year
- 2026: 10 · 2025: 22 · 2024: 18 · 2023: 20 · 2022: 31 · 2021: 29 · 2020: 33 · 2019: 18 · 2018: 20 · 2017: 36 · 2016: 37 · 2015: 34 · 2014: 27 · 2013: 29 · 2012: 26
- FWCI
- 13.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroscience (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Hungarian Scientific Research Fund (T032251)
- National Institutes of Health (5k01da000285-04)
- National Institute on Drug Abuse (DA 00285, DA11322, R01DA011322)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 41301, P30DK041301)
- National Institute of Neurological Disorders and Stroke (NS30549)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- CB1 receptor, amygdala, GABAergic neurotransmission, cholecystokinin interneurons, presynaptic modulation, endocannabinoids, lateral amygdala, basal amygdala, cannabinoid receptor agonists, CB1 knockout mice, emotional behavior
- MeSH terms
- Amygdala, Analgesics, Animals, Cannabinoids, Cholecystokinin, Cyclohexanols, gamma-Aminobutyric Acid, Interneurons, Male, Membrane Potentials, Morpholines, Naphthalenes, Nerve Net, Neural Inhibition, Synaptic Transmission, Organ Specificity, Receptors, Drug, Receptors, GABA-A, Rats, Wistar, Presynaptic Terminals, Mice, Knockout, Patch-Clamp Techniques, Receptors, Cannabinoid, Benzoxazines, Mice, Rats, Cannabinoid Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review